BioSenicBioSenic strengthens scientific team with... Dr Carole Nicco took up her position as CSO of Belgium-based BioSenic in mid-January. Nicco will oversee the development of BioSenic’s cell therapy and autoimmune disease platform pipeline and be responsible … more ➔
European Investment FundEIF appointed Chief Executive At the beginning of January 2023?Marjut Falkstedt will start as new Chief Executive of the European Investment Fund (EIF). more ➔
ValnevaValneva: New created position Valneva has appointed Dipal Patel as new Chief Commercial Officer and Management Board member. more ➔
Oxford BiomedicaOxford Biomedica gains new CEO Dr Frank Mathias, currently CEO at Rentschler Biopharma, will join Oxford Biomedica as CEO and Board Director in March 2023. more ➔
OxSonics TherapeuticsOxSonics Therapeutics with new Chief Execu...At the beginning of november, OxSonics Therapeutics has appointed Jérôme Marzinski as its Chief Executive Officer. more ➔
Aurobac TherapeuticsAMR joint venture Aurobac appoints CEO Aurobac Therapeutics has appointed Florence Séjourné as CEO. The French company is a joint venture, founded by Boehringer Ingelheim, Evotec and bioMérieux and focuses on combating antimicrobial resistance … more ➔
BioxodesBioxodes with management changes Bioxodes SA,based in Marche-en-Famenne, Belgium, has appointed Marc Dechamps as its new CEO. Company founder, Edmond Godfroid, will take up the post of Chief Operations Officer (COO) alongside his existing … more ➔
MaaT PharmaMaaT Pharma appointed new CSO French MaaT Pharma has appointed Nathalie Corvaïa as Chief Scientific Officer and will strengthens its R&D Activities in Immuno-Oncology. more ➔
MimetasMimetas: New Chair of the BoardLeiden-based Mimetas, specialist in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel (UCB, Belgium) as Chair of its Board of Directors. more ➔
Lytix BiopharmaLytix Biopharma: CBO-Position new filled Oslo-based Lytix Biopharma has a new Chief Business Officer. Stephen Worsley has started at the Norwegian immune-oncology company at the beginning of September. more ➔
